News

Amgen Announces Significant Survival Benefit for Lung Cancer Drug IMDELLTRA in Phase 3 Trial
Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim ...
Amgen: Imdelltra Data And Q1 Results Impress
Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...
KTLA15d
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA ® (tarlatamab-dlle ...
Zacks Investment Research on MSN14d
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...
Applied Clinical Trials Online7d
Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer
Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...
BlackDoctor.org8d
ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer
ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...
Amgen's Imdelltra Shows Lower Risk of Death, Other Benefits in Phase 3 Trial
Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.
Clinical Trials Arena14d
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed every year and 200,000 deaths occurring.